SEC Comment Letter for Inotiv, Inc. (NOTV) (CIK 0000720154) (NOTV) — Apr 10, 2006
Inotiv, Inc. (NOTV) (CIK 0000720154)
Date: April 10, 2006 · CIK: 0000720154 · Accession: 0000000000-06-016697
AI Filing Summary & Sentiment
Reasoning
Letter
Via Facsimile and U.S. Mail Mail Stop 6010 April 7, 2006 Mr. Peter T. Kissinger President, Chairman and CEO Bioanalytical Systems, Inc. 2701 Kent Avenue West Lafayette, Indiana 47906
Re: Bioanalytical Systems, Inc. Form 10-K for Fiscal Year Ended September 30, 2005 Filed January 18, 2006 File No. 0-23357
Dear Mr. Kissinger:
We have reviewed your March 28, 2006 response to our March 14, 2006 letter and have the following comment. In our comment, we ask you to provide us with information so we may better understand your disclosure. Please be as detailed as necessary in your explanation. After reviewing this information, we may raise additional comments.
Please understand that the purpose of our review process is to assist you in your compliance with the applicable disclosure requirements and to enhance the overall disclosure in your filing. We look forward to working with you in these respects. We welcome any questions you may have about our comments or on any other aspect of our review. Feel free to call us at the telephone numbers listed at the end of this letter.
Form 10-K for the year ended September 30, 2005
Note 3. Acquisitions, page 40 1. We have read your response to comment 2. Tell us whether the value you ascribed to the facility and recorded in your financial statements at the acquisition date assumed it was FDA compliant. If so, tell us what the intangible asset "FDA compliant facility" represents. If not, it would appear to us that this asset is really part of the facility you acquired and should be part of its basis that you depreciate over the facility`s useful life. * * * * Please respond to this comment within 10 business days or tell us when you will provide us with a response. Please furnish a letter that keys your response to our comment and provide the requested information. Detailed letters greatly facilitate our review. Please file your letter on EDGAR under the form type label CORRESP.
You may contact Sasha Parikh, Staff Accountant, at (202) 551- 3627 or Mary Mast, Review Accountant, at (202) 551-3613 if you have questions regarding the comments. In this regard, do not hesitate to contact me, at (202) 551-3679.
Sincerely,
Jim B. Rosenberg
Senior Assistant Chief
Accountant
Show Raw Text
<DOCUMENT>
<TYPE>LETTER
<SEQUENCE>1
<FILENAME>filename1.txt
<TEXT>
Via Facsimile and U.S. Mail
Mail Stop 6010
April 7, 2006
Mr. Peter T. Kissinger
President, Chairman and CEO
Bioanalytical Systems, Inc.
2701 Kent Avenue
West Lafayette, Indiana 47906
Re: Bioanalytical Systems, Inc.
Form 10-K for Fiscal Year Ended September 30, 2005
Filed January 18, 2006
File No. 0-23357
Dear Mr. Kissinger:
We have reviewed your March 28, 2006 response to our March
14,
2006 letter and have the following comment. In our comment, we
ask
you to provide us with information so we may better understand
your
disclosure. Please be as detailed as necessary in your
explanation.
After reviewing this information, we may raise additional
comments.
Please understand that the purpose of our review process is
to
assist you in your compliance with the applicable disclosure
requirements and to enhance the overall disclosure in your filing.
We look forward to working with you in these respects. We welcome
any questions you may have about our comments or on any other
aspect
of our review. Feel free to call us at the telephone numbers
listed
at the end of this letter.
Form 10-K for the year ended September 30, 2005
Note 3. Acquisitions, page 40
1. We have read your response to comment 2. Tell us whether the
value you ascribed to the facility and recorded in your financial
statements at the acquisition date assumed it was FDA compliant.
If
so, tell us what the intangible asset "FDA compliant facility"
represents. If not, it would appear to us that this asset is
really
part of the facility you acquired and should be part of its basis
that you depreciate over the facility`s useful life.
* * * *
Please respond to this comment within 10 business days or
tell
us when you will provide us with a response. Please furnish a
letter
that keys your response to our comment and provide the requested
information. Detailed letters greatly facilitate our review.
Please
file your letter on EDGAR under the form type label CORRESP.
You may contact Sasha Parikh, Staff Accountant, at (202)
551-
3627 or Mary Mast, Review Accountant, at (202) 551-3613 if you
have
questions regarding the comments. In this regard, do not hesitate
to
contact me, at (202) 551-3679.
Sincerely,
Jim B. Rosenberg
Senior Assistant Chief
Accountant
Peter T. Kissinger
Bioanalytical Systems, Inc.
April 7, 2006
Page 2 of 2
</TEXT>
</DOCUMENT>